



FORMULA NUMBER: 1990

FORMULA NAME: Chlortetracycline Bisulfate 1% Ointment, Veterinary

DOSAGE FORM: Ointment

FORMULA (Rx):

Ingredients	For: 100 grams	Lot#	RPh Initials
Chlortetracycline Bisulfate (Veterinary)	1 g		
Benzalkonium Chloride	10 mg		
Tetrasodium Pyrophosphate	50 mg		
Edetate Disodium Dihydrate	300 mg		
Lanolin (Anhydrous)	15 g		
Mineral Oil	15 g		
Paraffin	70 g		

SYNONYMS:

Aureomycin

USE/TYPE:

Human Use

Veterinary Use

Non-Sterile Preparation

CATEGORY:

AntiBacterial Tetracycline

AntiMycobacterial

AntiProtozoal

AntiRickettsial

NOTES:

Chlortetracycline hydrochloride may be substituted for the bisulfate salt. This same formula, utilizing the hydrochloride salt, is used for veterinary ophthalmic preparations.

SPECIALIZED EQUIPMENT:

METHOD OF PREPARATION:

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh and/or measure each ingredient.
3. Warm the paraffin and mineral oil over a water bath to about 50°C and maintain melted.
4. Add the anhydrous lanolin to the paraffin and mineral oil melt and mix well.
5. Triturate the chlortetracycline bisulfate, benzalkonium chloride, tetrasodium pyrophosphate and edetate disodium to fine powders.
6. Gradually incorporate the fine powders into the warmed mixture mixing well after each addition.

Chlortetracycline Bisulfate 1% Ointment, Veterinary
Formula # 1990 - Page 2

7. Allow to cool but still fluid and pour into containers.

8. Package and label.

LABELING:

Apply Very Sparingly to Affected Area

For Veterinary Use

Pregnant Women Must Not Handle this Medicine

For External Use Only

Keep Out of Reach of Children

PRESERVATION, PACKAGING AND STORAGE:

Tight, Light Resistant Container

Do Not Use After _____

Keep Out of Direct Sunlight

STABILITY:

A beyond-use date of 6 months can be used for this preparation.

ENDOTOXIN ASSESSMENT:

USE:

For topical administration to farm animals for superficial infections of amoeba and other organisms sensitive to tetracyclines including the treatment of Psittacosis and salmonella. Demethylchlortetracycline is used in a similar manner. Chlortetracycline hydrochloride was available as a 3% Ointment and an ear solution.

STANDARD OPERATING PROCEDURE FOR QUALITY CONTROL:

Assessments may include theoretical weight compared to actual weight, pH, specific gravity, active drug assay and color. Other observations: texture-surface, texture-spatula spread, appearance, feel, rheological properties and physical macroscopic observations should be noted.

REGULATORY CONTROL:

REFERENCES:

1. Gilman AG, Rall TW, Nies AS, et. al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 8th Ed. Pergamon Press Inc Elmsford NY, Elmsford NY; 1990:1120-1121.
2. Allen Loyd V Jr. The Basics of Compounding: Compounding Ointments and Pastes. International Journal of Pharmaceutical Compounding. 3(1); 1999:22.
3. Allen Loyd V Jr. Standard Operating Procedure for Physical Quality Assessment of Ointments/Creams/Gels. International Journal of Pharmaceutical Compounding. 2(4); 1998:308.
4. Ashworth Lisa D. Quality Control: Standard Operating Procedures--An Essential Tool for Developing Quality Preparations. International Journal of Pharmaceutical Compounding. 11(3); 2007:226.
5. United States Pharmacopeial Convention. United States Pharmacopeia 31-National Formulary 26. Chapter <795> United States Pharmacopeia, Rockville MD; 2008.
6. Trissel LA. Trissel's Stability of Compounded Formulations. 3rd Ed. American Pharmacists Association, Washington DC; 2005:101.
7. Attia MA, El-Sourdy HA, Shanaway SM. Stability of chlortetracycline hydrochloride and chloramphenicol in some ophthalmic ointment bases. Pharmazie. 40(); 1985:629-631.
8. Sparkes AH, Caney SM, Sturgess CP, Gruffydd-Hones TJ. The clinical efficacy of topical and systemic therapy for the treatment of feline ocular chlamydiosis. Journal of Feline Medicine & Surgery. 1(1); 1999:31-35.
9. Harms HF, Harms HF Jr, Harms GR. Aureomycin ointment used in infections of the eye, ear and skin in dogs and cats. Journal of the American Veterinary Medical Association. 117(885); 1950:462-464.
10. Ronchese F, Kern AB. Hairy tongue: Report of case following the use Aureomycin ointment. AMA Archives of Dermatology [Syphilol]. 67(5); 1953:503-506.
11. The United States Pharmacopeial Convention. USP-Pharmacists' Pharmacopeia. 2nd Ed., Rockville MD; 2008:775-779.
12. Gilman AG, Rall TW, Nies AS, et. al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 8th Ed. Pergamon Press Inc Elmsford NY, Elmsford NY; 1990:1117-1125.
13. Physicians' Desk Reference. 1969. 23rd Ed. Medical Economics, Inc; 1969:769-770.
14. Block JH, Beale JM Jr. Wilson and Grisvold's Textbook of Organic Medicinal & Pharmaceutical Chemistry. 11th Ed. Lippincott Williams & Wilkins, Baltimore; 2004:345-346.
15. United States Pharmacopeia. United States Pharmacopeia 32-National Formulary 27. Chapter <795> United States Pharmacopeial Convention, Rockville MD; 2009.
16. US FDA Office of Regulatory Affairs for Drug Evaluation and Research (CDER). U.S. 21 CFR Policy Guide (CPG) for FDA Staff and Industry: Sec.[§] 460.200 Pharmacy Compounding., www.fda.gov/ora/compliance; 2013.
17. United States Pharmacopeia 41-National Formulary 36 [May 2018]., Rockville MD; 2018.
18. Trissel LA, Ashworth LD, Ashworth J. Trissel's Stability of Compounded Formulations. 6th Ed. American Pharmacists Assn, Washington DC; 2018.

More information about this formula and its components available at the formula section of <https://CompoundingToday.com>

The International Journal of Pharmaceutical Compounding Inc., the parent of CompoundingToday.com, does not sponsor or initiate clinical investigations nor does it represent any agency, corporation or private individual.

While a great deal of effort has been expended to ensure the accuracy of the formulations contained here, IJPC accepts no liability for loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold IJPC and its officers, directors and employees harmless from any claim arising from use of or reliance on information contained therein.